Charles Sawyers has been a member of the Board ofDirectors since 2013. He qualifies as an independent Non-ExecutiveDirector. He is a member of the Research & DevelopmentCommittee and the Governance, Nomination and CorporateResponsibilities Committee.In the United States Sawyers is chair of the Human Oncologyand Pathogenesis Program at Memorial Sloan-Kettering CancerCenter, professor of medicine and of cell and developmentalbiology at the Weill Cornell Graduate School of Medical Sciences,and an investigator at the Howard Hughes Medical Institute. Heserves on US President Barack Obama’s National Cancer AdvisoryBoard and is past president of the American Association of CancerResearch and former president of the American Society for ClinicalInvestigation. He also is a member of the US National Academy ofSciences and Institute of Medicine.Sawyers received his M.D. from the Johns Hopkins School ofMedicine in the United States, and worked at the JonssonComprehensive Cancer Center at the University of California, LosAngeles, for nearly 18 years before joining Memorial SloanKetteringin 2006. An internationally acclaimed cancer researcher,he co-developed the Novartis cancer drug Gleevec/Glivec, and hasreceived numerous honors and awards, including the LaskerDeBakeyClinical Medical Research Award in2009. Sawyers is a member of the Scientific Advisory Board ofAgios Pharmaceuticals, Inc. in the United States.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
ORIC Pharmaceuticals | Founder | — | — | Detail |
Blueprint Medicines | Member of the Scientific Advisory Board | — | — | Detail |